| gap-pubmed-20260410- | What molecular mechanisms drive the contra-directional coupling between Nur77 an | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the clinical validation requirements for mitophagy-targeting therapeuti | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does mitophagy capacity become overwhelmed in Parkinson's and Alzheimer's di | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether mitophagy functions protectively versus contributing to | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does Reelin signaling transition from developmental neuronal layering to pos | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which Reelin signaling modulates s | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What are the specific epigenetic mechanisms linking DNA methylation, histone mod | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do environmental/dietary factors interact with genetic background to trigger | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether infiltrating monocytes become inflammatory macrophages v | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Do monocyte-derived microglia functionally differ from resident microglia in the | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms drive monocyte-to-microglia transformation and long-te | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Do ketone bodies enhance Aβ clearance in vivo and translate to cognitive benefit | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive ketone body-induced upregulation of LRP1, P-gp, | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can immunomodulatory therapies effectively target neuroinflammation in familial | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do GRN and C9orf72 mutations show heterogeneous tau/TDP-43 distributions unl | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link neuroinflammation to tau/TDP-43 pathology distribution in f | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do Aβ and tau differentially trigger mitochondrial DNA release to activate c | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the cell-type specificity of STING upregulation between microgli | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does APOE ε4 mechanistically upregulate cGAS-STING pathway components in AD | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What percentage of brain APOE4 must be converted to E3 to achieve meaningful AD | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the optimal brain-directed delivery method and dosing strategy for APOE4 | resolved | 0.84 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-pubmed-20260410- | How does exogenous human 4R-tau coaptate endogenous monkey 3R-tau during transne | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive the temporal switch from microglial to astroglia | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How can ADAM10 upregulation strategies be optimized to maximize neuroprotective | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms that regulate ADAM10 expression at tr | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do exercise duration, intensity, and type affect NDEV biomarkers in early AD | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do exercise-responsive pathways differ between neurons and peripheral tissue | open | 0.73 | 0.00 | 2026-04-10 | 0 | | exercise-physiology |
| gap-pubmed-20260410- | What mechanisms explain why APOE ε4 carriers show greater NDEV neuroprotective p | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TREM2-mediated lipid droplet accumulation in microglia contribute to wh | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link TREM2 signaling to autophagic-lysosomal pathway a | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does TREM2 deficiency paradoxically improve outcomes in chronic hypoperfusio | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the transition from normal microglial surveillance to abnormal p | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How can the cGAS/STING pathway in microglia be therapeutically targeted to delay | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanisms by which mitochondrial oxidative stress leads t | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does decreased microglial-vessel association contribute to diesel exhaust-in | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does TREM2 protein decrease globally while mRNA shows inverted-U patterns in | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms cause the inverted-U dose-response pattern of TREM2 and DAM mark | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do findings from scopolamine-induced amnesia translate to actual AD pathophy | open | 0.57 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms mediate sunflower seed oil's neuroprotective | open | 0.64 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do T cell-mediated autoimmune neurological conditions have limited treatment | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What specific factors determine breakdown of immune tolerance in neurological au | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do intracellular and extracellular autoantibody mechanisms interact in the i | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do ER stress and NF-κB activation mechanistically contribute to glymphatic s | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms link CCL2/CCR2 signaling to AQP4 depolarization in pos | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Can the CSF pT217/T217 × Aβ42/40 composite biomarker distinguish other genetic t | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do 3R+4R tauopathies specifically increase T217 phosphorylation while 4R tau | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive T217 phosphorylation in MAPT R406W carriers with | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What triggers the critical threshold where Aβ accumulation initiates the amyloid | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines individual resilience and brain reserve that modulates pre-demen | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms cause Aβ accumulation to begin in the third-fourth decades of li | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |